Histogenics (NASDAQ:HSGX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05), MarketWatch Earnings reports.
Shares of Histogenics stock traded down $0.03 on Friday, hitting $0.51. 1,795,036 shares of the company’s stock traded hands, compared to its average volume of 8,070,151. Histogenics has a one year low of $0.50 and a one year high of $3.35. The firm has a market cap of $15.64 million, a price-to-earnings ratio of -0.52 and a beta of 1.02.
Several brokerages have recently weighed in on HSGX. HC Wainwright set a $1.00 price target on Histogenics and gave the company a “buy” rating in a research note on Friday. Brookline Cap M reissued a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. Zacks Investment Research cut Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Needham & Company LLC increased their price target on Histogenics to $5.00 and gave the company a “buy” rating in a research note on Thursday, September 6th. Finally, BTIG Research cut Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target for the company. in a research note on Wednesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Histogenics has an average rating of “Hold” and an average price target of $3.25.
Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 22,927 shares in the last quarter. DRW Securities LLC bought a new stake in shares of Histogenics during the 2nd quarter valued at about $242,000. JPMorgan Chase & Co. bought a new stake in shares of Histogenics during the 1st quarter valued at about $320,000. Finally, Renaissance Technologies LLC boosted its position in shares of Histogenics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 22,133 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Featured Article: Why do companies issue stock splits?
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.